アデプタス・ヘルス

 ADPTのチャート


 ADPTの企業情報

symbol ADPT
会社名 Adeptus Health Inc (アデプタス・ヘルス)
分野(sector)   
産業(industry)   
業種    医療関連(Health Care)
概要 ―  アデプタス・ヘルスは米国の救急ケアプロバイダ―。テキサス州ヒュ―ストン、ダラス/フォ―トワ―ス、サンアントニオ、オ―スチン、コロラド州デンバ―とコロラドスプリングス、およびアリゾナ州フェニックスに独立型急病診療所「ファ―スト・チョイス・エマ―ジェンシ―・ル―プ」を所有、運営する。  Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
本社所在地 2941 Lake Vista Drive Lewisville TX 75067 USA
代表者氏名
代表者役職名
電話番号
設立年月日 41699
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 3202人
url www.adhc.com
nasdaq_url
adr_tso
EBITDA
終値(lastsale)
時価総額(marketcap)
時価総額
売上高
企業価値(EV)
当期純利益
決算概要
symbol ADPT
会社名 Adeptus Health Inc (アダプティブ・バイオテクノロジーズ(Adaptive Biotechnologies Corp))
分野(sector)   
産業(industry)   
業種 バイオテクノロジー & メディカル リサーチ   医療関連 (Health Care)
概要 ―  アデプタス・ヘルスは米国の救急ケアプロバイダ―。テキサス州ヒュ―ストン、ダラス/フォ―トワ―ス、サンアントニオ、オ―スチン、コロラド州デンバ―とコロラドスプリングス、およびアリゾナ州フェニックスに独立型急病診療所「ファ―スト・チョイス・エマ―ジェンシ―・ル―プ」を所有、運営する。  Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
本社所在地 2941 Lake Vista Drive Lewisville TX 75067 USA
代表者氏名 Chad M. Robins
代表者役職名 Executive Chairman Chief Executive Officer Co-Founder
電話番号 +1 206-659-0067
設立年月日 41699
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 3202人
url www.adhc.com
nasdaq_url
adr_tso
EBITDA EBITDA(百万ドル) -70.60000
終値(lastsale)
時価総額(marketcap)
時価総額 時価総額(百万ドル) 4567.03600
売上高 売上高(百万ドル) 85.07100
企業価値(EV) 企業価値(EV)(百万ドル) 4026.77700
当期純利益 当期純利益(百万ドル) -69.57000
決算概要 BRIEF: For the fiscal year ended 31 December 2019 Adaptive Biotechnologies Corp revenues increased 53% to $85.1M. Net loss applicable to common stockholders increased 50% to $69.6M. Revenues reflect Development revenue increase of 83% to $41.6M Sequencing revenue increase of 32% to $43.5M. Higher net loss reflects Research and development - Balancing increase of 84% to $66.8M (expense).

 ADPTのテクニカル分析


 ADPTのニュース

   Morgan Stanley maintains Adaptive Biotechnologies at Equalweight with a price target of $14.00  2023/05/06 02:33:37 Investing.com
https://www.investing.com/news/pro/adaptive-biotechnologies-corp-receives-investment-bank-analyst-rating-update-3074998
   Adaptive Biotechnologies Corporation (ADPT) Q1 2023 Earnings Call Transcript  2023/05/04 03:16:09 Seeking Alpha
Adaptive Biotechnologies Corporation (NASDAQ:NASDAQ:ADPT) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ETCompany ParticipantsKarina Calzadilla - Vice President of Investor…
   Adaptive Biotechnologies GAAP EPS of $0.40 beats by $0.78, revenue of $37.6M beats by $0.69M  2023/05/03 21:12:20 Seeking Alpha
Adaptive Biotechnologies press release (ADPT): Q1 GAAP EPS of $0.40 beats by $0.78.Revenue of $37.6M (-2.6% Y/Y) beats by $0.69M.2023 Financial GuidanceAdaptive…
   Adaptive Biotechnologies: Q1 Earnings Insights  2023/05/03 20:50:33 Benzinga
Adaptive Biotechnologies (NASDAQ: ADPT ) reported its Q1 earnings results on Wednesday, May 3, 2023 at 04:05 PM. Here''s what investors need to know about the announcement. Earnings Adaptive Biotechnologies missed estimated earnings by 5.26%, reporting an EPS of $-0.4 versus an … Full story available on Benzinga.com
   Adaptive Biotechnologies: Q1 Earnings Snapshot  2023/05/03 20:15:26 WTOP
SEATTLE (AP) — SEATTLE (AP) — Adaptive Biotechnologies Corp. (ADPT) on Wednesday reported a loss of $57.7 million in its…
   Adaptive Biotechnologies Corporation (ADPT) Q1 2023 Earnings Call Transcript  2023/05/04 03:16:09 Seeking Alpha
Adaptive Biotechnologies Corporation (NASDAQ:NASDAQ:ADPT) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ETCompany ParticipantsKarina Calzadilla - Vice President of Investor…
   Adaptive Biotechnologies GAAP EPS of $0.40 beats by $0.78, revenue of $37.6M beats by $0.69M  2023/05/03 21:12:20 Seeking Alpha
Adaptive Biotechnologies press release (ADPT): Q1 GAAP EPS of $0.40 beats by $0.78.Revenue of $37.6M (-2.6% Y/Y) beats by $0.69M.2023 Financial GuidanceAdaptive…
   Adaptive Biotechnologies: Q1 Earnings Insights  2023/05/03 20:50:33 Benzinga
Adaptive Biotechnologies (NASDAQ: ADPT ) reported its Q1 earnings results on Wednesday, May 3, 2023 at 04:05 PM. Here''s what investors need to know about the announcement. Earnings Adaptive Biotechnologies missed estimated earnings by 5.26%, reporting an EPS of $-0.4 versus an … Full story available on Benzinga.com
   Adaptive Biotechnologies: Q1 Earnings Snapshot  2023/05/03 20:15:26 WTOP
SEATTLE (AP) — SEATTLE (AP) — Adaptive Biotechnologies Corp. (ADPT) on Wednesday reported a loss of $57.7 million in its…
   Adaptive Biotechnologies Reports First Quarter 2023 Financial Results  2023/05/03 20:05:00 GlobeNewswire
SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2023.
   Adaptive Biotechnologies stock pops on Takeda pact for use of clonoSEQ test  2023/04/12 12:29:52 Seeking Alpha
Adaptive Biotechnologies (ADPT) is collaborating with Takeda (TAK) to use its clonoSEQ test to detect minimal residual disease for Takeda''s drugs. Read more here
   Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline  2023/04/12 11:30:00 GlobeNewswire
Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies
   Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ Assay Across Its Hematologic Malignancy Pipeline  2023/04/12 11:30:00 Wallstreet:Online
Collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose
   Adaptive Biotechnologies stock falls ~10% amid COO termination  2023/04/11 17:30:59 Seeking Alpha
Adaptive Biotechnologies (ADPT) stock fell after the company said it is terminating the services of its Chief Operating Officer Mark Adams by May. Read more here
   Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023  2023/04/06 20:05:00 GlobeNewswire
SEATTLE, April 06, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

 関連キーワード  (― 米国株 アデプタス・ヘルス ADPT )

 twitter  (公式ツイッターやCEOツイッターなど)